Table 1 Characteristics of included studies in meta-analysis
From: Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis
Year | First author | Country | Type of DCIS | Number of participants | TIL’s detection method | Cutoff of TIL’s point | Subtype of TILs | Treatment | Median follow up | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | Gaynor J. Bates et al. | UK | p-DCIS | 62 | IHC | 15 | FOXP3+ TILs | S & AT (RT/ HT) | 5.4 y | AR | [20] |
2016 | G. Pruneri et al. | Europe | DCIS | 1488 (set1: n = 1391; set2: n = 620) | HE | set1: < 1% vs. 35–50% | total p-TILs | S & AT (RT/ HT) | 8.2 y | IR | [8] |
set2: < 1% vs. > 50% | |||||||||||
2015 | Elizabeth Thompson et al. | USA | p-DCIS & i-DCIS | total p-TILs (n = 27) PD-L1+ TILs (n = 27) | HE & IHC | 50% | total p-TILs | S & AT | 80 m | IR | [9] |
PD-L+ TILs | |||||||||||
2017 | Shona Hendry et al. | Australia | p-DCIS | total p-TILs (n = 138) PD-L1+ TILs (n = 79) PD-L1+ TC(n = 79) | HE & IHC | TILs: 2%. PD-L1: 1% | total p-TILs | S & AT (RT/ HT) | TILs: 89 m PD-L1:39 m | IR | [7] |
PD-L1+ TILs | |||||||||||
PD-L1+ TC | |||||||||||
2018 | Michael S. Toss et al. | UK | training set: | training set | HE | training set: 5% | training set: | training set: | training set: 161 m | IR | [14] |
p-DCIS | (n = 150) | total p-TILs | S/ S & RT | ||||||||
validation set: | validation set | validation set: 20 | validation set: | validation set: | validation set: 109 m | ||||||
p-DCIS | (n = 534) | total t-TILs | S/ S & RT | ||||||||
2019 | Rajiv Dave et al. | Australia | p-DCIS | 423 | HE | 5% | total p-TILs | BCS | 119 m | IR | [21] |
2020 | Marie Colombe Agehozo et al. | Netherlands | p-DCIS | total p-TILs (n = 466) PD-L1+ TILs (n = 115) PD-L1+ TC(n = 115) | HE & IHC | 30% | total p-TILs | BCS/ MAS | 98 m | IR | [22] |
PD-L1+ TILs | |||||||||||
PD-L1+ TC | |||||||||||
2019 | Farbod Darvishian et al. | USA | p-DCIS | 69 | HE | 45% | total p-TILs | BCS | 6.7 y | IR | [11] |
2019 | Mieke Van Bockstal et al. | Belgium | p-DCIS | 211 | HE | 50% | total p-TILs | S & AT (RT/ HT) | 124 m | IR | [10] |
2020 | Aye Aye THIKE et al. | Singapore | DCIS | total p-TILs (n = 198) CD4+ TILs (n = 198) | HE & IHC | 20% | total p-TILs | S (BCS/ MAS) | TILs: 7.9 y CD4+: 7.2 y | AR | [23] |
CD4+ TILs | |||||||||||
2020 | Michael S. Toss et al. | UK | p-DCIS | total p-TILs (n = 508) FOXP3+ TILs(n = 406) PD-L1+ TILs (n = 383) CD4+ TILs (n = 403) CD8+ TILs (n = 402) | HE & IHC | 20 | total t-TILs | BCS | unknown | IR | [12] |
FOXP3+ TILs | |||||||||||
PD-L1+ TILs | |||||||||||
CD4+ TILs | |||||||||||
CD8+ TILs | |||||||||||
2020 | Alberto Farolfi et al. | Italy | p-DCIS | 496 | HE | 5% | total p-TILs | S/ S & RT | 56.4 y | IBE | [15] |
2021 | Fei-Fei Xu et al. | China | p-DCIS & | 135 | HE | 5 | total t-TILs | BCS/ BCS & RT | 53 m | IR | [13] |
m-DCIS |